APOA5 Antikörper (N-Term)
Kurzübersicht für APOA5 Antikörper (N-Term) (ABIN965570)
Target
Alle APOA5 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- N-Term
-
Aufreinigung
- Purified by antigen-specific affinity chromatography.
-
Immunogen
- Polyclonal antibody produced in rabbits immunizing with a synthetic peptide corresponding to N-terminal residues of human APOA5 (Apolipoprotein A-V precursor)
-
-
-
-
Applikationshinweise
- ELISA, Western blotting: 1µg/ml for 2hrs.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Buffer
- This antibody is stored in PBS, 50% glycerol
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
-
- APOA5 (Apolipoprotein A-V (APOA5))
-
Andere Bezeichnung
- APOA5
-
Hintergrund
- APOA5(Apolipoprotein A-V) is a minor apolipoprotein mainly associated with HDL and to a lesser extent with VLDL. APOA5 may also be associated with chylomicrons. APOA5 is an important determinant of plasma triglyceride (TG) levels by both being a potent stimulator of apo-CII lipoprotein lipase (LPL) TG hydrolysis and a inhibitor of the hepatic VLDLTG production rate (without affecting the VLDL-apoB production rate). Three common alleles are known: allele APOA5*1, APOA5*2 and APOA5*3. The APOA5*2 haplotype, which consists of 3 non-coding SNPs, is present in approximately 16% of Caucasians and is associated with increased plasma triglyceride concentrations. APOA5*3 haplotype is defined by the rare Ser-19-Trp substitution. Together, the APOA5*2 and APOA5*3 haplotypes are found in 25 to 50% of African Americans, Hispanics, and Caucasians.
-
Pathways
- Regulation of Lipid Metabolism by PPARalpha, Lipid Metabolism
Target
-